Analysis of the clinical efficacy of Shenmai Injection and bronchus artery intervention therapy on metaphase or terminal lung cancer
Objective To investigate the clinical efficacy and safety of Shenmai Injection and bronchus artery intervention therapy on the treatment of metaphase or terminal lung cancer. Methods 82 cases of metaphase or terminal lung cancer were divided into the observation group(with 53 cases) and the control group(with 29 cases). The control group was treated with bronchus artery intervention therapy, while the observation group was additionally treated Shenmai Injection. Observations were carried out about the clinical efficacy and toxic and side effects of both groups. Results The effective treatment rate of the observation group was 71.69%, significantly higher than 55.17% of the control group(P <0.05). The cases in the observation group with nausea and vomiting as well as leucopenia were fewer than those in the control group(P <0.05). The one-year rate of survivors and two-year rate of survivors of the observation group were significantly higher than those of the control group(P <0.05). Conclusion With the qualities of effectively improving clinical efficacy and reducing toxic and side effects, Shenmai.
Metaphase or terminal lung cancerBronchus artery interventional therapyShenmai Injection
NETL
NSTL
万方数据
维普
